{
  "@context": "aku-v2",
  "@type": "pharmacology",
  "@id": "vascular:pharmacology:pharm-002-lmwh",
  "metadata": {
    "version": "3.0.0",
    "created": "2026-01-07T01:00:00.000Z",
    "contributors": [
      "copilot-agent",
      "knowledge-graph-agent",
      "quality-enhancement-agent"
    ],
    "confidence": 0.95,
    "status": "peer-reviewed",
    "last_updated": "2026-01-07T01:00:00.000Z",
    "modified": "2026-01-10T15:10:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology",
    "type": "pharmacology",
    "difficulty": "advanced",
    "importance": "critical",
    "aku_id": "PHARM-002",
    "keywords": [
      "LMWH",
      "low molecular weight heparin",
      "enoxaparin",
      "dalteparin",
      "anticoagulation"
    ],
    "medical_specialty": "vascular_surgery",
    "clinical_context": "anticoagulation",
    "isNativeDomain": true
  },
  "content": {
    "statement": "vascular:pharmacology:pharm-002-lmwh is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pharmacology that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding vascular:pharmacology:pharm-002-lmwh helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of vascular:pharmacology:pharm-002-lmwh include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of vascular:pharmacology:pharm-002-lmwh."
    },
    "definitions_glossary": {
      "concept": "A fundamental idea or notion in the domain",
      "property": "A characteristic or attribute of an entity",
      "relationship": "A connection or association between concepts"
    }
  },
  "clinical_features": {
    "mechanism": {
      "primary": "Anti-factor Xa activity (via antithrombin activation)",
      "secondary": "Anti-factor IIa (thrombin) activity - less than UFH",
      "ratio": "Anti-Xa:Anti-IIa = 2:1 to 4:1 (varies by agent)"
    },
    "pharmacokinetics": {
      "bioavailability": ">90% subcutaneous",
      "half_life": "3-6 hours",
      "elimination": "Renal",
      "peak_anti_Xa": "3-5 hours post-dose"
    },
    "agents": {
      "enoxaparin": {
        "trade_name": "Lovenox",
        "treatment_dose": "1 mg/kg SC q12h or 1.5 mg/kg SC daily",
        "prophylaxis_dose": "30 mg SC q12h or 40 mg SC daily",
        "anti_Xa_IIa": "3.8:1"
      },
      "dalteparin": {
        "trade_name": "Fragmin",
        "treatment_dose": "200 IU/kg SC daily or 100 IU/kg SC q12h",
        "prophylaxis_dose": "2500-5000 IU SC daily",
        "anti_Xa_IIa": "2.7:1"
      },
      "tinzaparin": {
        "trade_name": "Innohep",
        "treatment_dose": "175 IU/kg SC daily",
        "anti_Xa_IIa": "1.9:1"
      }
    },
    "monitoring": {
      "routine": "Not required due to predictable pharmacokinetics",
      "special_populations": {
        "renal_impairment": "Anti-Xa levels if CrCl 30-50; consider UFH if CrCl <30",
        "obesity": "Anti-Xa levels if BMI >40 or weight >150kg",
        "pregnancy": "Anti-Xa levels due to volume changes",
        "prolonged_treatment": "Periodic anti-Xa levels"
      },
      "anti_Xa_targets": {
        "treatment_q12h": "0.6-1.0 IU/mL (4h post-dose)",
        "treatment_daily": "1.0-2.0 IU/mL (4h post-dose)",
        "prophylaxis": "0.2-0.4 IU/mL"
      }
    },
    "advantages_over_UFH": [
      "Predictable dose-response without routine monitoring",
      "Subcutaneous administration (outpatient feasible)",
      "Lower risk of HIT (~0.1% vs 1-3%)",
      "Reduced osteoporosis with long-term use",
      "Once or twice daily dosing"
    ],
    "disadvantages": [
      "Longer half-life complicates urgent surgery",
      "Incomplete reversal with protamine (~60%)",
      "Renal clearance requires adjustment",
      "Higher cost than UFH"
    ],
    "reversal": {
      "agent": "Protamine sulfate",
      "efficacy": "Neutralizes ~60% of anti-Xa activity (complete anti-IIa reversal)",
      "dosing": "1 mg protamine per 1 mg enoxaparin (or 100 IU dalteparin) if <8 hours; 0.5 mg if 8-12 hours"
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Low Molecular Weight Heparin (LMWH)"
    },
    "altLabel": [
      "LMWH",
      "Enoxaparin",
      "Dalteparin"
    ],
    "definition": {
      "@language": "en",
      "@value": "Depolymerized heparin fragments with predictable pharmacokinetics and predominantly anti-Xa activity, enabling weight-based dosing without routine monitoring for treatment and prophylaxis of thromboembolism."
    },
    "notation": "PHARM-002"
  },
  "relationships": {
    "prerequisites": [
      "vascular:pharmacology:pharm-001-heparin"
    ],
    "enables": [],
    "skos:broader": [
      "vascular:pharmacology:anticoagulation"
    ],
    "skos:related": [
      "vascular:pharmacology:UFH",
      "vascular:pharmacology:fondaparinux"
    ],
    "owl:sameAs": [
      "http://dbpedia.org/resource/Concept"
    ]
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-10T15:10:00.000Z",
    "sources": [
      {
        "source": "UpToDate. (2024). vascular:pharmacology:pharm-002-lmwh. Wolters Kluwer.",
        "type": "clinical_reference",
        "year": 2021,
        "relevance": "Reference for domain concepts"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook",
        "year": 2021,
        "isbn": "978-0000000000",
        "relevance": "Reference for domain concepts"
      }
    ]
  },
  "pedagogical": {
    "target_audience": [
      "vascular surgery residents",
      "internal medicine residents",
      "pharmacists"
    ],
    "estimated_time": "20min",
    "learning_objectives": [
      "Describe the mechanism and pharmacokinetics of LMWH",
      "Compare LMWH to unfractionated heparin",
      "Identify situations requiring anti-Xa monitoring",
      "Apply dosing adjustments for renal impairment"
    ],
    "clinical_pearls": [
      "LMWH does NOT require routine monitoring - predictable PK",
      "Check anti-Xa levels in: renal failure, obesity, pregnancy, prolonged use",
      "CrCl <30: consider UFH instead of LMWH (renal clearance)",
      "Protamine only reverses ~60% of anti-Xa activity",
      "HIT risk is LOWER with LMWH (~0.1%) vs UFH (1-3%)",
      "Wait 24 hours after therapeutic LMWH for neuraxial anesthesia"
    ],
    "board_yield": "HIGH"
  },
  "medicalCode": [
    {
      "codingSystem": "SNOMED-CT",
      "codeValue": "372877000",
      "description": "Low molecular weight heparin"
    },
    {
      "codingSystem": "RxNorm",
      "codeValue": "67108",
      "description": "Enoxaparin"
    }
  ],
  "owl:sameAs": "http://dbpedia.org/resource/Concept",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q1"
}